We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSLN
RNS Number : 9003U
Silence Therapeutics PLC
17 July 2018
Grant of Restricted Stock Units
17 July 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has today granted nominal cost restricted stock units ('RSUs') to David Horn Solomon, the Company's Chief Executive Officer, under the Silence Therapeutics plc 2018 Long Term Incentive Plan. Details of the grant are summarised below.
Award of Restricted Stock Units:
Director Position RSUs Awarded Total RSUs Held David Horn Solomon CEO 401,338 401,338 ---------- ------------- ----------------
These nominal cost RSUs will vest in full on 16 July 2021. The RSUs are subject to achievement of the performance condition that the Company's share price must be maintained above 157p for a period of 30 continuous days prior to vesting. The RSUs are exercisable over the period of 7 years from the date of vesting. Claw-back and malus provisions apply. There is a one-year holding period post exercise. Each RSU entitles the holder to subscribe for an Ordinary Share at a subscription price of 5 pence per Ordinary Share equating to the nominal value.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated a) Name David Horn Solomon ------------------------------- ----------------------------------------------- 2 Reason for the notification -------------------------------------------------------------------------------- a) Position/status Chief Executive Officer ------------------------------- ----------------------------------------------- b) Initial notification/Amendment Initial notification ------------------------------- ----------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor -------------------------------------------------------------------------------- a) Name Silence Therapeutics plc ------------------------------- ----------------------------------------------- b) LEI 213800SSURRJBX85SQ91 ------------------------------- ----------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted -------------------------------------------------------------------------------- a) Description of the financial Ordinary shares of 5 pence each instrument, type of instrument ISIN for Silence Therapeutics plc Ordinary Identification code Shares GB00B9GTXM62 ------------------------------- ----------------------------------------------- b) Nature of the transaction Grant of restricted stock units under the Silence Therapeutics plc 2018 Long Term Incentive Plan ------------------------------- ----------------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) 5 pence per share (subscription price) 401,338 ------------------------------- ----------------------------------------------- d) Aggregated information - Aggregated volume N/A - Price ------------------------------- ----------------------------------------------- e) Date of the transaction 17 July 2018 ------------------------------- ----------------------------------------------- f) Place of the transaction Outside a trading venue ------------------------------- -----------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +44 (0) 20 3457 Annalisa Jenkins, Executive Chair 6900 David Horn Solomon, Chief Executive Officer David Ellam, Chief Financial Officer Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0) 20 7418 James Steel/ Oliver Jackson 8900 Media & IR Enquiries Tel: +44 (0) 20 3714 Optimum Strategic Communications 1788 Mary Clark/ Eva Haas/ Hollie Vile silence@optimumcomms.com IR Enquiries - US Tel: +1 (212) 213 Burns McClellan 0006 John Grimaldi Silence.Therapeutics@burnsmc.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new modality of genetic medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome and be engineered to specifically silence the production of disease-associated proteins. Using enabling delivery systems, Silence has achieved an additional level of specificity by delivering therapeutic RNA molecules exclusively to target cells. Silence's proprietary technology platform provides an effective, safe and highly potent modular approach well suited to tackling life-threatening diseases. Silence aims on being a clinical stage company in 2019, while progressing a pipeline of earlier stage candidates against important gene targets directed at areas of high unmet medical need. In parallel, Silence continues to evolve its patent portfolio as new discoveries emerge from its innovative efforts to develop the next generation of RNAi medicines.
Silence has out-licensed technology to Quark Pharmaceuticals for use in Delayed Graft Function and Acute Kidney Injury. Both programmes are now in phase III. For more information, please visit: http://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHBGGDRUXBBGIR
(END) Dow Jones Newswires
July 17, 2018 10:00 ET (14:00 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions